The findings indicated that foscarbidopa/foslevodopa showed a significantly greater increase in “on” time without any troublesome dyskinesia (2.72 [0.52] vs 0.97 [0.50] hours; difference: 1.75 hours; 95% CI 0.46 to 3.05; p = .0083), and a significantly greater reduction in “off” time (−2.75 [0.50] vs −0.96 [0.49] hours; difference: −1.79 hours, −3.03 to −0.54; p = .0054) compared with the carbidopa/levodopa regimen. Additionally, the investigators observed improvements in “on” time as early as week 1, and these persisted throughout the 12-week duration.1,3
"For too long, the PD community has had limited treatment options for advanced disease. Due to the progressive nature of the disease, oral medications are eventually no longer as effective at motor symptom control and surgical treatment may be required," said Robert A. Hauser, MD, MBA, professor of neurology, director of the Parkinson's and Movement Disorder Center, University of South Florida, in a news release. “This new, non-surgical regimen provides continuous delivery of levodopa morning, day and night.”1
Further, adverse events (AEs) were reported by approximately 85% (n = 63) of patients who received foslevodopa/foscarbidopa compared with 63% (n = 42) of those who received carbidopa/levodopa. The rate of serious AEs were similar between the 2 groups, with foslevodopa/foscarbidopa reporting 6 (8%) and carbidopa/levodopa reporting 4 (6%). In the foslevodopa/foscarbidopa group, the most common AEs were infusion site AEs such as erythema (n = 20; 27%), pain (n = 19; 26%), cellulitis (n = 14; 19%), and oedema (n = 9; 12%), of which most were mild to moderate in severity. Additionally, AEs led to premature discontinuation of the study drug in about 22% (n = 16) of participants in the foslevodopa/foscarbidopa group versus 1% (n = 1) in the carbidopa/levodopa.3
“People living with advanced PD experience daily challenges as a result of uncertainty in managing motor fluctuations, especially as their disease progresses,” said Roopal Thakkar, MD, executive vice president, research & development, and chief scientific officer, AbbVie, in the news release. “We are proud to bring this innovation to patients who may benefit from motor symptom control through continuous 24-hour administration of [foscarbidopa/foslevodopa].”1
REFERENCE
2. Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease. ClinicalTrials.gov identifier: NCT04380142. Updated November 18, 2022. Accessed October 17, 2024. https://clinicaltrials.gov/study/NCT04380142
3. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2024;21(12):1099-1109. doi:10.1016/S1474-4422(22)00400-8